<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03273413</url>
  </required_header>
  <id_info>
    <org_study_id>17-0678</org_study_id>
    <nct_id>NCT03273413</nct_id>
  </id_info>
  <brief_title>Statin Therapy in Patients With Early Stage ADPKD</brief_title>
  <official_title>Statin Therapy in Patients With Early Stage ADPKD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn if pravastatin is helpful in slowing down the progression of kidney
      disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has
      been approved by the Food and Drug Administration (FDA) for adults for treatment of
      hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this
      study as an investigational drug for treatment of ADPKD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy
      and benefits of pravastatin therapy in adults with ADPKD by evaluating 1) kidney volume as
      measured by kidney magnetic resonance imaging (MRI); 2) renal blood flow as measured by
      kidney magnetic resonance angiography (MRA); 3) kidney function as assessed by Glofil-125;
      and 4) plasma and urine protein markers that will allow a better understanding of how
      pravastatin works in ADPKD. These parameters will be measured at baseline and after 2 years
      of pravastatin or placebo treatment in 150 patients with ADPKD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, parallel study design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Kidney Volume</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Total kidney volume as assessed by renal MRI, at baseline and after 2 years of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Blood Flow</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Renal blood flow, as assessed by renal MRA, at baseline and after 2 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kidney Function</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Glomerular filtration rate (GFR), as assessed by Glofil-125, at baseline and after 2 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Inflammatory Markers</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Plasma levels of inflammatory cytokines and growth factors at baseline and after 2 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Markers of Oxidative Stress</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Plasma levels of oxidative stress markers at baseline and after 2 years of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Epithelial Cells Imaging</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Urinary epithelial cell protein expression, as assessed by immunofluorescence, at baseline and after 2 years of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>ADPKD</condition>
  <condition>Autosomal Dominant Polycystic Kidney</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy</description>
    <arm_group_label>Pravastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ADPKD

          -  Total kidney volume &gt;500 mL

          -  Estimated glomerular filtration rate (GFR) â‰¥60 mL/min/1.73m^2

          -  Controlled blood pressure &lt;140/80 mmHg

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Diabetes mellitus

          -  Renal disease, renal cancer, single kidney, recent renal surgery, or acute kidney
             injury

          -  Unstable angina

          -  Coronary artery disease

          -  Prior ischemic stroke

          -  Other clinical indication for a statin

          -  History of hospitalizations within the last 3 months

          -  Hepatic impairment or liver function abnormalities

          -  Secondary hypercholesterolemia or hypocholesterolemia

          -  Use of tolvaptan, gemfibrozil, other fibrates, niacin, clarithromycin, or cyclosporine

          -  Hypersensitivity to statins

          -  Immunosuppressive therapy within the last year

          -  Clinical contraindication for an MRI (i.e. implants, pacemaker, claustrophobia)

          -  Hypersensitivity to iodine

          -  Pregnant or breast feeding

          -  Current tobacco use

          -  Alcohol abuse or dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Chonchol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Z Bispham, MS</last_name>
    <phone>303-724-1692</phone>
    <email>nina.bispham@ucdenver.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beverly Farmer, RN</last_name>
    <phone>303-724-7790</phone>
    <email>beverly.farmer@ucdenver.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver Anschutz Medical Campus</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Z Bispham, MS</last_name>
      <phone>303-724-1692</phone>
      <email>nina.bispham@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beverly Farmer, RN</last_name>
      <phone>303-724-7790</phone>
      <email>beverly.farmer@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michel B Chonchol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014 May;9(5):889-96. doi: 10.2215/CJN.08350813. Epub 2014 Apr 10.</citation>
    <PMID>24721893</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2017</study_first_submitted>
  <study_first_submitted_qc>September 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pravastatin</keyword>
  <keyword>Statin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

